• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rodman & Renshaw initiated coverage on Achieve Life Sciences with a new price target

    11/14/24 7:20:56 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ACHV alert in real time by email
    Rodman & Renshaw initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00
    Get the next $ACHV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACHV

    DatePrice TargetRatingAnalyst
    11/14/2024$12.00Buy
    Rodman & Renshaw
    9/27/2024$20.00Strong Buy
    Raymond James
    5/10/2023$8.00 → $20.00Buy
    Maxim Group
    10/4/2021$25.00Buy
    Alliance Global Partners
    6/23/2021$23.00Outperform
    Oppenheimer
    More analyst ratings

    $ACHV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Achieve Life Sciences Inc.

      SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      5/9/25 1:01:44 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Achieve Life Sciences Inc.

      SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      4/30/25 10:59:09 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by Achieve Life Sciences Inc.

      DEF 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      4/28/25 4:09:05 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

      ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025 SEATTLE and VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association (JAMA) Internal Medicine. ORCA-3 was the

      4/21/25 11:19:48 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

      Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Hig

      3/11/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Wan Jerry

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      1/30/25 4:54:30 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/12/24 12:14:09 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Achieve Life Sciences Inc.

      SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/4/24 10:59:37 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Achieve Life Sciences Inc. (Amendment)

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      5/20/24 5:01:27 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Financials

    Live finance-specific insights

    See more

    $ACHV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ACHV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

      Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Hig

      3/11/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

      SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its fourth quarter and year-end 2024 financial results and provide an update on the cytisinicline development program on Tuesday, March 11, 2025, at 8:30 AM EDT. To access the webcast, please use the following link 4Q24 Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 1 201-689-7817 (International) and refer

      3/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Rodman & Renshaw initiated coverage on Achieve Life Sciences with a new price target

      Rodman & Renshaw initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00

      11/14/24 7:20:56 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Raymond James initiated coverage on Achieve Life Sciences with a new price target

      Raymond James initiated coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00

      9/27/24 7:26:18 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Maxim Group reiterated coverage on Achieve Life Sciences with a new price target

      Maxim Group reiterated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $20.00 from $8.00 previously

      5/10/23 11:34:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/6/24 4:49:23 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Leadership Updates

    Live Leadership Updates

    See more
    • Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

      SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea

      1/10/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

      SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, information technology, legal and other key administrative functions, ensuring effective planning and execution to support organizational objectives. "Mark's extensive financial, strategic, and opera

      12/9/24 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments